A large number of licencees remained unchecked; sample analysis reports were issued late and where sample was found not of standard quality, action for recalling and issuing alert was initiated with inordinate delay. Destruction of substandard drugs was not monitored and subsequent batches were not checked. Risk of manufacturing, distribution and sale of substandard drugs was high with serious implications for health and even lives of general public.